Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 124 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 Load more HOT NEWS Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... FDA Approvals Expand Initial Treatment Options for Multiple Myeloma
